Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China SXT PharmaceuticalsFRA:2RY2 +8,446.70%19 Equity-to-Asset is 0.86 as of Mar. 2026, which is 76% above its 10-year median of 0.49. GuruFocus rates FRA:2RY2 with a GF Score™ of 19/100. The stock has 8 warning signs investors should review. Among 1,006 Drug Manufacturers companies, China SXT Pharmaceuticals ranks better than 88.97% on this metric.
China SXT Pharmaceuticals (FRA:2RY2) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
China SXT Pharmaceuticals Equity-to-Asset Related Terms
China SXT Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2RY2 vs CBIH, UPC, NPHC: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's Equity-to-Asset falls into.
China SXT Pharmaceuticals Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
China SXT Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals (FRA:2RY2) has a Equity-to-Asset of 0.86 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on China SXT Pharmaceuticals and its competitors. This is 76% above median its historical median of 0.49. Over the past decade, China SXT Pharmaceuticals' Equity-to-Asset has ranged from 0.34 to 0.86. According to the industry distribution chart, China SXT Pharmaceuticals ranks #111 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 11%.
Is China SXT Pharmaceuticals' Equity-to-Asset too high?
China SXT Pharmaceuticals' current Equity-to-Asset of 0.86 is 76% above median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.86. The Drug Manufacturers industry median Equity-to-Asset is 0.61. China SXT Pharmaceuticals' value of 0.86 is 41% above this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #111 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Equity-to-Asset compare to CBIH and UPC?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #111 out of 1006 companies for Equity-to-Asset. This places China SXT Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. China SXT Pharmaceuticals' value of 0.86 is 41% above this benchmark. Historically, China SXT Pharmaceuticals' own Equity-to-Asset has ranged from 0.34 to 0.86 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 0.61, China SXT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current Equity-to-Asset of 0.86 is 41% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current Equity-to-Asset is 0.86, which is 76% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (FRA:2RY2) has a current Equity-to-Asset of 0.86. The current Equity-to-Asset is 0.86, which is 76% above median its 10-year median of 0.49 and 41% above the Drug Manufacturers industry median of 0.61. China SXT Pharmaceuticals' overall GF Score™ is 19/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY2), the current Equity-to-Asset is 0.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
19GF Score
Get the complete analysis for FRA:2RY2
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2RY2 has been successfully added to your 
